Back to search results

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

Abroad (travel likely)Recruiting

Conditions

Recessive Dystrophic Epidermolysis Bullosa

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Lucile Packard Children's Hospital, Palo Alto, California, United States

    Contact: Study coordinator (Thomas Buschbacher) · tbusch@stanford.edu · 650-313-0354
    Contact: Principal Investigator (Joyce Teng)

  • Children's Hospital Colorado, Aurora, Colorado, United States

    Contact: Study coordinator (Matthew Brien) · matthew.brien@childrenscolorado.org · 7207770802
    Contact: Principal Investigator (Anna Bruckner)

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Department of Dermatology, Chicago, Illinois, United States

    Contact: Study coordinator (Alyssa Appleman) · alyssa.appleman@northwestern.edu · 3125035927
    Contact: Principal Investigator (Amy Paller)

  • University of Texas Medical Branch, Galveston, Texas, United States

    Contact: Study coordinator (Lindsay Allen) · listurm@utmb.edu · 4092662678
    Contact: Principal Investigator (Lindy Ross)
View source on ClinicalTrials.gov(opens in a new tab)